shr3680 + shr3162

**SHR3680 + SHR3162** is a combination of two investigational agents developed for oncology indications. **SHR3680** (also known as rezvilutamide) is a novel, orally administered androgen receptor (AR) antagonist. It inhibits AR nuclear translocation, transcriptional activity, and downregulates AR overexpression in prostate cancer cells, effectively suppressing prostate-specific antigen (PSA) secretion without partial agonist activity[1][2][4]. SHR3680 shows lower CNS penetration and seizure risk compared to enzalutamide and is a strong inducer of CYP3A4 and CYP2B6[2]. **SHR3162** is referenced as a companion investigational molecule, but detailed mechanistic and clinical data are not available in the provided sources. The combination likely intends to augment AR pathway inhibition or expand activity within prostate cancer or potentially other hormone-driven malignancies; however, specific details about SHR3162's mechanism are lacking. Primary indication for SHR3680 is metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC)[1][2][3].

Other names

shr3680shr-3680shr 3680shr3162shr-3162shr 3162rezvilutamide